The LRIG2 Antibody (PAC05780) is a polyclonal antibody designed for research involving LRIG2, a member of the leucine-rich repeats and immunoglobulin-like domains (LRIG) family of proteins. LRIG2 is known to play a role in regulating cell growth and differentiation, particularly in the context of cancer development and progression. This antibody, raised in rabbits, is highly specific to human LRIG2 protein and is validated for use in various applications including Western blot, immunohistochemistry, and immunofluorescence. Its ability to bind to LRIG2 protein enables researchers to detect and analyze its expression levels in different cell types and tissues, making it an ideal tool for studies in cancer biology and cell signaling pathways.
LRIG2 has been shown to have tumor-suppressive properties in certain types of cancer, making it a potential target for cancer therapy and drug development. By understanding the role of LRIG2 in cancer progression, researchers can gain insights into new treatment strategies and personalized medicine approaches. The LRIG2 Antibody (PAC05780) is a valuable tool for further exploration of LRIG2 function and its implications in cancer biology.
Western Blot. Positive WB detected in: HepG2 whole cell lysate. All lanes: LRIG2 antibody at 3.5µg/ml. Secondary. Goat polyclonal to rabbit IgG at 1/50000 dilution. Predicted band size: 119 kDa. Observed band size: 119 kDa.
Immunofluorescence staining of Hela cells with PACO59780 at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
Synonyms:
Leucine-rich repeats and immunoglobulin-like domains protein 2 (LIG-2), LRIG2, KIAA0806 LIG2
